Travere Therapeutics, Inc.
corporate_fare Company Profile
Travere Therapeutics, Inc. (NASDAQ:TVTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for TVTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-02, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for TVTX spans 8-K, 10-Q, 424B5, FWP.
Recent high-impact activity:
- FILSPARI Sales Jump 120% to $200M as Travere Posts Q3 Results
- FILSPARI Data Show 75% IgAN Remission and Slower eGFR Decline in FSGS
- Travere Therapeutics Names Bradley Campbell CEO as Eric Dube Steps Down
- Travere Q2: FILSPARI Sales Surge 96%, FSGS Approval, and a $1B+ Pipeline Deal
- Travere Q2: FILSPARI Sales Surge 96% to $141M, FSGS Launch Gains Traction
Financial Snapshot
Short Interest & Short Volume
4.74 days to coverFINRA reported short interest of 9,561,082 shares in TVTX as of the October 30, 2026 settlement, a 12.4% decrease from the prior period — about 4.7 days to cover at its recent average daily volume. On November 20, 2026, 42.0% of TVTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.